|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-8-16
|
|
pubmed:abstractText |
Salvage therapy for patients with refractory/relapsed B-cell non-Hodgkin lymphoma (NHL) is based on polychemotherapy, followed by high-dose therapy and autologous stem cell transplantation in eligible patients (HDT/ASCT). R-DHAP combines rituximab with cisplatin, cytarabine, and dexamethasone.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
2152-2669
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
262-9
|
|
pubmed:meshHeading |
pubmed-meshheading:20709662-Adult,
pubmed-meshheading:20709662-Aged,
pubmed-meshheading:20709662-Aged, 80 and over,
pubmed-meshheading:20709662-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:20709662-Cytarabine,
pubmed-meshheading:20709662-Dexamethasone,
pubmed-meshheading:20709662-Drug Therapy, Combination,
pubmed-meshheading:20709662-Drug Toxicity,
pubmed-meshheading:20709662-Female,
pubmed-meshheading:20709662-Humans,
pubmed-meshheading:20709662-Lymphoma, B-Cell,
pubmed-meshheading:20709662-Lymphoma, Non-Hodgkin,
pubmed-meshheading:20709662-Male,
pubmed-meshheading:20709662-Middle Aged,
pubmed-meshheading:20709662-Organoplatinum Compounds,
pubmed-meshheading:20709662-Recurrence,
pubmed-meshheading:20709662-Retrospective Studies,
pubmed-meshheading:20709662-Salvage Therapy,
pubmed-meshheading:20709662-Treatment Outcome,
pubmed-meshheading:20709662-Young Adult
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Rituximab, dexamethasone, cytarabine, and oxaliplatin (R-DHAX) is an effective and safe salvage regimen in relapsed/refractory B-cell non-Hodgkin lymphoma.
|
|
pubmed:affiliation |
Pharmacie Department, AP-HP, Hôpital Saint-Louis, Paris, France.
|
|
pubmed:publicationType |
Journal Article,
Evaluation Studies
|
